WebAug 26, 2024 · FibroGen, Inc. (NASDAQ: FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors of FibroGen, passed away … WebAug 26, 2024 · SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and …
FibroGen (FGEN) Reports Passing of CEO Thomas B. Neff
WebAug 31, 2024 · Thomas Neff, founder of a biotech company known for its anemia treatment, died last Sunday at age 65. The cause of death was not reported. Neff founded FibroGen … WebSep 12, 2024 · Nan Chen 1 , Chuanming Hao 1 , Xiaomei Peng 1 , Hongli Lin 1 , Aiping Yin 1 , Li Hao 1 , Ye Tao 1 , Xinling Liang 1 , Zhengrong Liu 1 , Changying Xing 1 , Jianghua Chen 1 , Laimin Luo 1 , Li Zuo 1 , Yunhua Liao 1 , Bi-Cheng Liu 1 , Robert Leong 1 , Chunrong Wang 1 , Cameron Liu 1 , Thomas Neff 1 , Lynda Szczech 1 , Kin-Hung P Yu 1 mcw plastic surgery residents
FibroGen (FGEN) Stock Price & Analysis - TipRanks
WebNeff Thomas B similar filings. 23 Feb 18 Fibrogen Inc; 14 Feb 18 Fibrogen Inc; 14 Feb 17 Fibrogen Inc; 16 Feb 16 Fibrogen Inc; Related company. FGEN. FibroGen Inc NASDAQ. … WebThomas B Neff's 39 research works with 2,308 citations and 10,865 reads, including: Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney … WebApr 11, 2024 · Pros. 1) New leadership walks the talk - transparent, genuine, and breaking down functional silos 2) Business growth - co. is gaining approvals ex US and new … life physics uwaterloo